In papillary thyroid cancer TERT promoter mutations have a worst impact on outcome than BRAF mutations
M Muzza, C Colombo, MC Proverbio… - Endocrine …, 2015 - endocrine-abstracts.org
TERT promoter mutations (chr5: 1 295 228C> T e chr5: 1 295 250C> T) were recently
described in thyroid tumors, with a prevalence ranging 8–25% in papillary thyroid cancer
(PTC). We and others reported that these mutations strongly associate with a poor outcome
in differentiated thyroid cancers. Aim of the present study was to further investigate the
prognostic role of both TERT promoter (TERT MUT) and BRAF V600E mutations in a larger
series of 216 PTCS with a long follow-up (median: 77 months). We also evaluated the …
described in thyroid tumors, with a prevalence ranging 8–25% in papillary thyroid cancer
(PTC). We and others reported that these mutations strongly associate with a poor outcome
in differentiated thyroid cancers. Aim of the present study was to further investigate the
prognostic role of both TERT promoter (TERT MUT) and BRAF V600E mutations in a larger
series of 216 PTCS with a long follow-up (median: 77 months). We also evaluated the …
以上显示的是最相近的搜索结果。 查看全部搜索结果